SCHEMBL1824176

SCHEMBL1824176

Oc1ccc(C=Cc2ccc(O)c(O)c2)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 4/20 1.00
NQO2 P16083 4/20 0.81
KDM4E B2RXH2 4/20 0.77
CYP3A4 P08684 3/20 0.77
ALDH1A1 P00352 3/20 0.77
HSD17B10 Q99714 3/20 0.77
ALOX5 P09917 3/20 0.77
POLB P06746 3/20 0.77
ALOX12 P18054 2/20 0.77
CYP2C9 P11712 2/20 0.77
HIF1A Q16665 2/20 0.77
MEN1 O00255 2/20 0.77
LMNA P02545 2/20 0.77
TTR P02766 2/20 0.77
MMP2 P08253 2/20 0.77
MAPT P10636 2/20 0.77
THRB P10828 2/20 0.77
MMP9 P14780 2/20 0.77
HPGD P15428 2/20 0.77
PMP22 Q01453 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31706727 1.00 LCK (1.00) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL1824175 1.00 LCK (1.00) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL30631591 1.00 LCK (1.00) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL10335571 0.97 LCK (0.94) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL1931423 0.90 LCK (0.81) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL29958569 0.90 LCK (0.81) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL1820186 0.90 LCK (1.00) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL1820187 0.90 LCK (1.00) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL4607871 0.90 LCK (0.81) LCKNQO2KDM4ECYP3A4ALDH1A1
SCHEMBL4607867 0.90 LCK (0.81) LCKNQO2KDM4ECYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436538-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION Merryvital AG (CH) 2024-10-02 EP claimed
EP-3654929-B1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE OREAL (FR) 2024-05-29 EP claimed
WO-2023094852-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION MERRYVITAL AG (CH) 2023-06-01 WO claimed
EP-3654929-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2020-05-27 EP claimed
WO-2019016153-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2019-01-24 WO claimed
EP-2315583-B1 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE YVERY (FR) 2018-05-09 EP claimed
US-20110184072-A1 FORMULATION INTENDED TO IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE PECHERE LAURENT 2011-07-28 US claimed
EP-2005941-A2 Cellular rejuvenation compounds Henkel AG & Co. KGaA (DE) 2008-12-24 EP claimed
EP-1068864-B1 Use of at least one hydroxystilbene as glycation inhibitor OREAL (FR) 2005-02-09 EP claimed
EP-1064931-B1 Cosmetic composition containing at least one hydroxystilbene and ascorbic acid OREAL (FR) 2004-12-15 EP claimed
EP-1234571-A1 Topical composition containing a hydroxystilbene and a polyol L'OREAL (FR) 2002-08-28 EP claimed
US-6440433-B1 TREATING MENOPAUSAL SKIN DISORDERS; APPLYING TOPICAL MIXTURE TO IMPART AGING RESISTANCE; ACTIVATING SKIN FIBROBLAST PROLIFERATION SOCIETE L'OREAL S.A. (FR) 2002-08-27 US claimed
EP-1068864-A1 Use of at least a hydroxystilbene as a glycation inhibitor L'OREAL (FR) 2001-01-17 EP claimed
EP-1064931-A1 Cosmetic composition containing at least an hydroxystilbene and ascorbic acid L'OREAL (FR) 2001-01-03 EP claimed
US-6147121-A TOPICALLY APPLYING HYDROXYSTILBENE DERIVATIVE TO TREAT SKIN AGING AND WRINKLES SOCIETE L'OREAL S.A. (FR) 2000-11-14 US claimed
US-6124364-A Desquamation/epidermal renewal of the skin and/or combating skin aging SOCIETE L'OREAL S.A. (FR) 2000-09-26 US claimed
EP-0953346-A1 Use of at least a hydroxystilbebe in a skin fortifying composition L'OREAL (FR) 1999-11-03 EP claimed
EP-0953344-A1 Use of at least one hydroxystilbene in a composition to stimulate desquamation of the skin and compositions containing it L'OREAL (FR) 1999-11-03 EP claimed
EP-0953345-A1 Use of at least a hydroxystilbene as an agent for decreasing micro-organism adhesion L'OREAL (FR) 1999-11-03 EP claimed
US-4954659-A FOOD PRESERVATIVE CHEMEX PHARMACEUTICALS, INC. (US) 1990-09-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184072-A1 FORMULATION INTENDED TO IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE FABP2, SI, SLC10A2 LCK 3753/4885NQO2 1315/4885KDM4E 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.